Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 639 • 2019 ACR/ARP Annual Meeting
African-American Risk of Proteinuria After SLE Diagnosis Increases Throughout Thirty Years of Followup
Michelle Petri¹ and Jessica Li ¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: African-Americans lupus nephritis is more common than in Caucasians, more severe and more likely to lead to end stage renal disease. We asked whether…
Abstract Number: 697 • 2019 ACR/ARP Annual Meeting
Differing Opinions on Clinical Research Between Healthcare Providers and Lupus Patients
Cristina Arriens¹, Dylan Forciea ², Judith James ¹ and Joan T. Merrill ³, ¹Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Oseberg, Oklahoma City, OK, ³Okalahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Although SLE disproportionately affects minority racial groups, this population is significantly under-represented in clinical trials, increasing risk for underpowered, incorrect conclusions in race-based sub-group…
Abstract Number: 1018 • 2019 ACR/ARP Annual Meeting
Renal Single Cell Genomics Links Type II Interferon and Lupus Nephritis in African-Americans
Andrea Fava¹, Yuji Zhang ², Jill Buyon ³, Chaim Putterman ⁴, Nir Hacohen ⁵, Arnon Arazi ⁵, Celine Berthier ⁶, Deepak Rao ⁷, Michael Brenner ⁸, David Wofsy ⁹, Anne Davidson ¹⁰, Mathias Kretzler ¹¹, David Hildeman ¹², E. Steve Woodle ¹², Betty Diamond ¹⁰, Thomas Tuschl ¹³, Evan Der ¹⁴, Hemant Suryawanshi ¹³, H. Michael Belmont ¹⁵, Peter Izmirly ¹⁶, Robert Clancy ¹⁶, The Accelerating Medicines Partnership ¹⁷ and Michelle Petri ¹⁸, ¹Johns Hopkins University, Baltimore, ²University of Maryland, Baltimore, ³NYU School of Medicine, New York, ⁴Albert Einstein College of Medicine, New York, NY, ⁵Broad Institute, Cambridge, ⁶University of Michigan, Ann Arbor, MI, ⁷Brigham and Women's Hospital, Boston, MA, ⁸Brigham and Women’s Hospital:, Boston, ⁹UCSF, San Francisco, ¹⁰Feinstein Institutes for Medical Research, Manhasset, ¹¹University of Michigan, Ann Arbor, ¹²University of Cincinnati, Cincinnati, ¹³Rockefeller Research Laboratories, New York, ¹⁴Albert Einstein College of Medicine, New York, ¹⁵New York University School of Medicine, Ney York, ¹⁶New York University School of Medicine, New York, ¹⁷Multiple Organizations, USA, ¹⁸Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Compared to Caucasian, African-American ethnicity is associated with a higher risk of developing systemic lupus erythematosus, lupus nephritis, high-risk histological features, resistance to treatment,…
Abstract Number: 1146 • 2019 ACR/ARP Annual Meeting
Therapy of Lupus Nephritis with Mycophenolate Mofetil in Routine Clinical Practice: Response Rates and Role of Ethnicity
Prathima Anandi ¹, Alyson Dickson ², Vivian Kawai ², C. Michael Stein ² and Cecilia Chung³, ¹Vanderbilt University Medical Center, Nashville, ²Vanderbilt University Medical Center, Nashville, TN, ³Vanderbilt University, Nashville, TN
Background/Purpose: Randomized clinical trials have reported that 56-68% of patients with lupus nephritis treated with mycophenolate mofetil (MMF) respond to therapy, and a randomized clinical…
Abstract Number: 1577 • 2019 ACR/ARP Annual Meeting
The Impact of the New American College of Cardiology/American Heart Association Definition of Hypertension on Cardiovascular Events in Systemic Lupus Erythematosus
Konstantinos Tselios¹, Dafna Gladman ², Jiandong Su ³ and Murray Urowitz ⁴, ¹University Health Network, University of Toronto, Toronto, ²Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ³University Health Network, University of Toronto, Toronto, ON, Canada, ⁴University Health Network, University of Toronto, Toronto, Canada
Background/Purpose: The 2017 guidelines by the American College of Cardiology/American Heart Association (ACC/AHA) define hypertension at a threshold of ≥130/80mmHg for the systolic and diastolic…
Abstract Number: 1619 • 2019 ACR/ARP Annual Meeting
Early Vascular Ageing as a Predictor of Future Cardiovascular Events and Mortality in Systemic Lupus Erythematosus Patients: A Prospective Cohort Study
Viola Signorini¹, Dina Zucchi ², Chiara Tani ³, Rosa Maria Bruno ⁴, Elena Elefante ³, Chiara Stagnaro ⁵, Linda Carli ³, Alice Parma ³, Francesco Ferro ⁶, Sabina Armenia ⁷, lorenzo Ghiadoni ⁸, Stefano Taddei ⁷ and Marta Mosca ³, ¹Rheumatology Unit, Department of clinical and experimental medicine, University of Pisa, pisa, Toscana, Italy, ²Rheumatology Unit. Department of clinical and experimental medicine, University of PIsa, Pisa, Toscana, Italy, ³Rheumatology Unit, Department of clinical and experimental medicine, University of Pisa, Pisa, Italy, ⁴Hypertension Unit, Department of clinical e experimental medicine, University di Pisa, Pisa, Italy, ⁵Azienda Ospedaliero Universitaria Pisana, University of Pisa, Pisa, Italy, ⁶Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, Pisa, Italy, ⁷Hypertension Unit, Department of clinical and experimental medicine, University of Pisa, pisa, Italy, ⁸Emergency Unit, Department of clinical and experimental medicine, University of Pisa, pisa, Italy
Background/Purpose: Systemic Lupus Erithematosus (SLE) is associated with increased cardiovascular (CV) risk compared with general population; an accelerated atherosclerosis is considered the main underlying mechanism.…
Abstract Number: 1845 • 2019 ACR/ARP Annual Meeting
Physical Inactivity Is a Risk Factor for Incident Depression in Systemic Lupus Erythematosus
Laura Trupin¹, Sarah Patterson ¹, Louise Murphy ², Maria Dall'Era ¹, Jinoos Yazdany ³ and Patricia Katz ¹, ¹University of California, San Francisco, San Francisco, CA, ²Centers for Disease Control and Prevention, Division of Population Health, Atlanta, ³UCSF Division of Rheumatology, San Francisco, CA
Background/Purpose: Physical activity can prevent and reduce depression, but there is little research on the relationship between physical inactivity and subsequent onset of depression in…
Abstract Number: 2038 • 2019 ACR/ARP Annual Meeting
Antibodies to Malondialdehyde-acetaldehyde (MAA) Protein Adduct as a Biomarker for Cardiovascular Manifestations in Systemic Lupus Erythematosus
Yangsheng Yu ¹, Michelene Hearth-Holmes ², Tammy Wang ¹, Perio D Lopez ³, Carmen Tineo ⁴, G Paulino ⁴, Michael Duryee ², Geoffrey Thiele ⁵, Ted Mikuls ⁵, Esthela Loyo ⁴ and Kaihong Su², ¹University of Nebraska Medical Center, Omaha, ²University of Nebraska Medical Center, Omaha, NE, ³Georgetown University, Washington DC, ⁴Hospital Regional Universitario José Ma Cabral Baez, San Diego, Dominican Republic, ⁵VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by devastating end-organ manifestations. Cardiovascular disease (CVD) is a leading cause for premature death…
Abstract Number: 2522 • 2019 ACR/ARP Annual Meeting
Frequency and Early Prediction of Hydroxychloroquine Induced Retinopathy in SLE
Jessica Li¹, Daniel Goldman ² and Michelle Petri ¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: In 2016, the American Academy of Ophthalmology (AAO) published recommendations designed to reduce hydroxychloroquine induced retinopathy via early detection and reduction of hydroxychloroquine dosing…
Abstract Number: 2558 • 2019 ACR/ARP Annual Meeting
Profiling of Gene Expression, Immune Cell Subtypes, and Circulating Protein Biomarkers in Systemic Lupus Erythematosus Patients Treated with the Selective Immunoproteasome Inhibitor, KZR-616
R Andrea Fan¹, Janet Anderl ¹, Brian Tuch ², Darrin Bomba ¹, Niti Goel ³ and Christopher Kirk ¹, ¹Kezar Life Sciences, South San Francisco, CA, ²Kezar Life Sciences, south san francisco, ³Kezar Life Sciences, Duke University School of Medicine, South San Francisco, CA
Background/Purpose: KZR-616 is a selective inhibitor of the immunoproteasome, the form of proteasome found predominantly in immune cells. In nonclinical studies, KZR-616 blocks acute production…
Abstract Number: 2785 • 2019 ACR/ARP Annual Meeting
Cancer Risk in a Large Inception SLE Cohort: Effects of Age, Smoking, and Medications
Sasha Bernatsky¹, Rosalind Ramsey-Goldman ², Murray Urowitz ³, John Hanly ⁴, Caroline Gordon ⁵, Michelle Petri ⁶, Ellen M Ginzler ⁷, Daniel J Wallace ⁸, Sang-Cheol Bae ⁹, Juanita Romero-Diaz ¹⁰, MA Dooley ¹¹, Christine Peschken ¹², David A Isenberg ¹³, Anisur Rahman ¹⁴, Susan Manzi ¹⁵, Soren Jacobsen ¹⁶, S Sam Lim ¹⁷, Ronald F Van Vollenhoven ¹⁸, Ola Nived ¹⁹, Diane Kamen ²⁰, Cynthia Aranow ²¹, Jill Buyon ²², Guillermo Ruiz-Irastorza ²³, Ian Bruce ²⁴, Dafna Gladman ²⁵, Paul Fortin ²⁶, Joan T. Merrill ²⁷, Jorge Sanchez-Guerrero ²⁸, Kenneth C Kalunian ²⁹, Kristjan Steinsson ³⁰, Manuel Ramos ³¹, Asad Zoma ³², Thomas Stoll ³³, Munther A Khamashta ³⁴, Murat Inanc ³⁵ and Ann E Clarke ³⁶, ¹Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²Northwestern University, Chicago, IL, ³University Health Network, University of Toronto, Toronto, ON, Canada, ⁴Queen Elizabeth II Health Science Centre (Nova Scotia Rehab Site), Halifax, NS, Canada, ⁵University of Birmingham, Birmingham, United Kingdom, ⁶Johns Hopkins University School of Medicine, Baltimore, MD, ⁷State University of New York Downstate Medical Center, Brooklyn, NY, ⁸Cedars-Sinai Medical Centre, Beverly Hills, CA, ⁹Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ¹⁰Instituto Nacional de Ciencias Medicas y Nutricion Salvador, Zubiran Vasco de Quiroga, Mexico City, Mexico, ¹¹UnC Kidney Centre, Chapel Hill, NC, ¹²University of Manitoba, Winnipeg, Canada, ¹³Centre for Rheumatology, London, United Kingdom, ¹⁴University College London, London, United Kingdom, ¹⁵Allegheny Health Network, Pittsburg, PA, ¹⁶Copenhagen Lupus and Vasculitis Clinic, Copenhagen, Denmark, ¹⁷Emory University, Atlanta, GA, ¹⁸Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands, ¹⁹Lund University, Lund, Sweden, ²⁰Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charleston, SC, ²¹Feinstein Institute for Medical Research, Manhasset, NY, ²²NYU School of Medicine, New York, ²³Autoimmune Diseases Unit, Hospital Universitario Cruces, Barakaldo, Spain, Barakaldo, Spain, ²⁴University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, ²⁵Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ²⁶Division de Rhumatologie, Département de Médecine, CHU de Québec – Université Laval, Axe maladies infectieuses et inflammatoires, Centre de recherche du CHU de Québec – Université Laval, Canada, Quebec, QC, Canada, ²⁷Okalahoma Medical Research Foundation, Oklahoma City, OK, ²⁸Toronto Western Hospital, Toronto, ON, Canada, ²⁹UC San Diego School of Medicine, LaJolla, CA, ³⁰Landspitali, University Hospital, Reykjavik, Iceland, ³¹Department of Internal Medicine, Hospital Nuestra Señora del Prado, Talavera, Talavera, Spain, Talavera, Spain, ³²Lanarkshire Centre for Rheumatology, Hairmyres Hospital, East Kilbride, Scotland, United Kingdom, ³³University of Glasgow, Kilbride, Scotland, United Kingdom, ³⁴King's College London School of Medicine, London, United Kingdom, ³⁵Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ³⁶University of Calgary, Calgary, AB, Canada
Background/Purpose: Many studies of cancer risk in SLE are limited by small sample size or use of administrative data, which rely on billing code diagnoses…
Abstract Number: 73 • 2019 ACR/ARP Annual Meeting
Potent Anti-neutrophil Properties of the Natural Compound 6-Gingerol in Models of Lupus and Antiphospholipid Syndrome
Ramadan Ali¹, Julia Weiner ¹, Alex Gandhi ¹, Shanea Estes ¹ and Jason Knight ², ¹University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI
Background/Purpose: 6-gingerol, the major bioactive compound of ginger root, is known to have anti-inflammatory and anti-oxidative effects. Indeed, ginger has been employed for millennia as…
Abstract Number: 641 • 2019 ACR/ARP Annual Meeting
A Novel Method to Analyze Circulating Immune Complexes Predicts Disease Activity and Severity in Systemic Lupus Erythematosus and Rheumatoid Arthritis
Anders Bengtsson ¹, Helena Tyden ¹, Tiffany Pan ², J. Lee Nelson ³ and Christian Lood², ¹Lund University, Lund, Sweden, ²University of Washington, Seattle, ³Fred Hutchinson Cancer Research Center, Seattle
Background/Purpose: Circulating immune complexes (IC) are detectable in a variety of systemic inflammatory diseases, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), reflecting the…
Abstract Number: 700 • 2019 ACR/ARP Annual Meeting
Sleep Quality Among Patients with Systemic Lupus Erythematosus
Alexandra Schwab¹ and Diane Kamen ², ¹Medical University of South Carolina, Charleston, SC, ²Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charleston, SC
Background/Purpose: Poor sleep quality is a frequent concern among patients with systemic lupus erythematosus (SLE) and contributes to fatigue and other comorbidities. This study investigates…
Abstract Number: 1019 • 2019 ACR/ARP Annual Meeting
Type I Interferon Levels Vary with Regional Ancestry in European-derived SLE Cohorts
Justine Shum¹, Yogita Ghodke-Puranik ², Regine Tipon ², Jessica Dorschner ³, Danielle Vsetecka ³, Shreyasee Amin ⁴, Ashima Makol ⁵, Floranne Ernste ⁴, Thomas Osborn ⁵, Kevin Moder ³, Vaidehi Chowdhary ³, Uma Thanarajasingam ⁶, Vilija Oke ⁷, Iva Gunnarsson ⁷, Agneta Zickert ⁷, Maria Zervou ⁸, Elisabet Svenungsson ⁹, George Goulielmos ⁸ and Timothy Niewold ², ¹NYU School of Medicine, New York, ²Colton Center for Autoimmunity, NYU School of Medicine, New York, ³Mayo Clinic, Rochester, ⁴Mayo Clinic Rochester, Rochester, MN, ⁵Mayo Clinic Minnesota, rochester, MN, ⁶Mayo Clinic, Rochester, MN, ⁷Karolinska Institutet, Stockholm, Sweden, ⁸University of Crete, Crete, Greece, ⁹Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Type I interferon (IFN) is an important mediator in the pathogenesis of systemic lupus erythematosus. Serum type I IFN levels clearly vary between SLE…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].